Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody | C107P

Catalog No.	C107P
Product Name	Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody | C107P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Protein Tyrosine Kinase 7
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human Protein Tyrosine Kinase 7 (PTK7) monoclonal antibody cofetuzumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade cofetuzumab biosimilar specifically binds to the PTK7 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade cofetuzumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade cofetuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C107P: Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.

Background

What is cofetuzumab biosimilar research grade? Cofetuzumab is a humanized IgG1-kappa monoclonal antibody against PTK7, which is a tumor-associated antigen (TAA) and overexpressed on a variety of cancer cells. Cofetuzumab pelidotin is an antibody-drug conjugate (ADC) composed of cofetuzumab linked, via a cleavable valine-citrulline linker, to an analog of the auristatin microtubule inhibitor dolastatin 10, auristatin-0101, with potential antineoplastic activity. Upon administration, cofetuzumab pelidotin targets and binds to PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, auristatin-0101 binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and apoptosis of PTK7-expressing tumor cells. Cofetuzumab biosimilar uses the same protein sequences as the therapeutic antibody cofetuzumab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Please remember our product information: Cofetuzumab Biosimilar, Human PTK7 Monoclonal Antibody: C107P Syd Labs

No more offers for this product!